Halozyme Therapeutics, Inc. (HALO) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は San Diego, CA, アメリカ. 現CEOは Helen I. Torley.
HALO を有する IPO日 2004-03-16, 350 名の正社員, に上場 NASDAQ Global Select, 時価総額 $7.97B.
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company headquartered in San Diego, California, with operations across the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. The company's core proprietary technology, ENHANZE, is based on a recombinant human hyaluronidase enzyme (rHuPH20) that enables subcutaneous delivery of injectable biologics, including monoclonal antibodies and other therapeutic molecules. Halozyme develops and commercializes multiple products across oncology, immunology, and rare disease areas, including Hylenex, RITUXAN HYCELA, HYQVIA, and collaborates with leading pharmaceutical companies such as Roche, Pfizer, AbbVie, and Bristol-Myers Squibb on various therapeutic programs targeting cancer, autoimmune diseases, and infectious diseases. Founded in 1998, the company leverages its advanced drug delivery platform to enhance the efficacy and patient convenience of treatments across multiple therapeutic areas.
